Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful
The article, "Demonstrated Clinical Utility of Target Selector™ ctDNA testing: Liquid Biopsy EGFR mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLC patients," was published in the
"
"With our first peer-reviewed publication of the new year, we continue to expand the clinical evidence supporting the use of our Target Selector™ platform," said
About
Non-small cell lung cancer (NSCLC) is not a single disease, but a collection of cancer types whose pathology is classified by histology (cells) and molecular profiling (genetic and protein biomarkers). The discovery of molecular alterations in genes, such as EGFR, ALK, and ROS1, have improved physicians' ability to manage advanced lung cancer. Identifying these markers is crucial to offering patients the most advanced treatments available. The NCCN,
For more information on
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to increase physician adoption of our Target Selector assays, and whether additional case studies will be published in the future supporting the use of our liquid biopsy platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/published-case-series-indicates-the-ability-of-biocepts-liquid-biopsy-testing-to-identify-actionable-biomarkers-when-tissue-biopsy-is-unsuccessful-300789624.html
SOURCE